Find Paid Clinical Trials in Maine

Paid Clinical Trials and Focus Groups

Find Paid Clinical Trials

Paid Clinical Trials in Maine

Top of Directory » All Locations » United States » Maine




  • Subjective Evaluation of Air Optix Aqua Amongst a Subset of the Contact Lens Wearing Population

    Condition:   Myopia
    Interventions:   Device: Air Optix Aqua (lotrafilcon B);   Device: habitual contact lenses
    Sponsor:   Novartis
    Recruiting - verified November 2009

  • Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720

    Condition:   Leukemia
    Intervention:   Other: laboratory biomarker analysis
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia

    Condition:   Leukemia
    Interventions:   Genetic: fluorescence in situ hybridization;   Genetic: mutation analysis;   Genetic: nucleic acid sequencing;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Other: flow cytometry;   Other: laboratory biomarker analysis
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial

    Condition:   Leukemia
    Interventions:   Genetic: DNA analysis;   Genetic: Southern blotting;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis

    Condition:   Ulcerative Colitis
    Interventions:   Drug: Asacol (mesalamine), High Dose;   Drug: Asacol (mesalamine), Low Dose
    Sponsor:   Procter and Gamble
    Recruiting - verified October 2009

  • Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

    Conditions:   Lymphoma;   Lymphoproliferative Disorder
    Interventions:   Other: biologic sample preservation procedure;   Other: informational intervention
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

    Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
    Recruiting - verified November 2009

  • TAXUS Libertē Post Approval Study

    Condition:   Coronary Artery Disease
    Interventions:   Device: TAXUS Liberté Paclitaxel-Eluting Coronary Stent;   Drug: prasugrel;   Drug: placebo;   Drug: aspirin
    Sponsors:   Boston Scientific Corporation;   Eli Lilly and Company;   Daiichi Sankyo Inc.
    Not yet recruiting - verified November 2009

  • A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds

    Condition:   Human Papillomavirus Infection
    Interventions:   Biological: V503;   Biological: Comparator: Menactra™ (Concomitant);   Biological: Comparator: Adacel™ (concomitant);   Biological: Comparator: Menactra™ (Non-Concomitant);   Biological: Comparator: Adacel™ (Non-concomitant)
    Sponsor:   Merck
    Recruiting - verified November 2009

  • Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

    Condition:   Arthritis, Rheumatoid
    Interventions:   Drug: CP-690,550;   Drug: CP-690,550;   Drug: Placebo;   Drug: CP-690,550;   Drug: Placebo;   Drug: CP-690,550
    Sponsor:   Pfizer
    Recruiting - verified November 2009

  • Study of VX-770 in Cystic Fibrosis Subjects Age 12 and Older Homozygous for the F508del-CFTR Mutation

    Condition:   Cystic Fibrosis
    Interventions:   Drug: VX-770;   Drug: Placebo
    Sponsors:   Vertex Pharmaceuticals Incorporated;   Cystic Fibrosis Foundation
    Recruiting - verified November 2009

  • Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

    Conditions:   Kidney Cancer;   Precancerous/Nonmalignant Condition
    Interventions:   Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Study of Trastuzumab-MCC-DM1 (T-DM1) in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

    Condition:   Metastatic Breast Cancer
    Interventions:   Drug: pertuzumab;   Drug: trastuzumab-MCC-DM1
    Sponsor:   Genentech
    Recruiting - verified October 2009

  • Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Subjects With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)

    Conditions:   Primary Hypercholesterolemia;   Mixed Hyperlipidemia
    Interventions:   Drug: SCH 900271;   Drug: SCH 900271;   Drug: SCH 900271;   Drug: SCH 900271;   Drug: SCH 900271;   Drug: Placebo
    Sponsor:   Schering-Plough
    Recruiting - verified October 2009

  • Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma

    Condition:   Asthma
    Interventions:   Drug: QMF149 Twisthaler®;   Drug: Mometasone Twisthaler®
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified November 2009

  • 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD)

    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: NVA237;   Drug: Placebo to NVA;   Drug: Tiotropium
    Sponsor:   Novartis
    Recruiting - verified November 2009

  • A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye

    Condition:   Dry Eye
    Interventions:   Drug: SAR 1118;   Drug: Placebo
    Sponsor:   SARcode Corporation
    Recruiting - verified November 2009

  • Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

    Condition:   Brain and Central Nervous System Tumors
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Samples From Patients With Lung Cancer

    Condition:   Lung Cancer
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

    Conditions:   Chordoma;   Desmoid Tumor;   Sarcoma
    Interventions:   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

    Condition:   Glioblastoma Multiforme
    Interventions:   Device: NovoTTF-100A device;   Drug: Temozolomide
    Sponsor:   NovoCure Ltd.
    Recruiting - verified November 2009

  • Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

    Condition:   Neuroblastoma
    Interventions:   Genetic: loss of heterozygosity analysis;   Other: cytology specimen collection procedure;   Procedure: biopsy
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study to Test GSK256073 in Patients With Dyslipidemia

    Condition:   Dyslipidaemia
    Interventions:   Drug: Niaspan;   Drug: GSK256073;   Drug: GSK256073;   Drug: GSK256073;   Drug: Placebo;   Drug: GSK256073;   Drug: GSK256073
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

    Conditions:   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

    Condition:   Leukemia
    Interventions:   Genetic: DNA analysis;   Genetic: DNA methylation analysis;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: high performance liquid chromatography;   Other: laboratory biomarker analysis
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

    Conditions:   Leukemia;   Neoplasm of Uncertain Malignant Potential;   Unspecified Childhood Solid Tumor, Protocol Specific
    Intervention:   Other: cytology specimen collection procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma

    Condition:   Lymphoma
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

    Condition:   Sarcoma
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting Tumor Samples From Patients With Gynecological Tumors

    Condition:   Cancer
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial

    Conditions:   Leukemia;   Lymphoma
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study Evaluating a Planned Transition From Tacrolimus to Sirolimus in Kidney Transplant Recipients

    Conditions:   Graft Rejection;   Kidney Transplant
    Interventions:   Drug: Tacrolimus;   Drug: Sirolimus
    Sponsor:   Wyeth
    Recruiting - verified October 2009

  • A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Drug: bevacizumab;   Drug: docetaxel;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: cyclophosphamide;   Drug: pegfilgrastim
    Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   Genentech;   US Oncology Research
    Recruiting - verified October 2009

  • A Study of Patients With Relapsing Remitting Multiple Sclerosis

    Condition:   Relapsing-Remitting Multiple Sclerosis
    Interventions:   Drug: LY2127399;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting - verified November 2009

  • Study Evaluating the Effects of Neratinib in Women With Early Stage Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Drug: neratinib;   Other: placebo
    Sponsor:   Wyeth
    Recruiting - verified November 2009

  • Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

    Conditions:   Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma
    Interventions:   Drug: bendamustine and rituximab;   Drug: R-CVP or R-CHOP
    Sponsor:   Cephalon
    Recruiting - verified November 2009

  • Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    Conditions:   Leukemia;   Lymphoma
    Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: bortezomib;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

    Conditions:   Breast Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Musculoskeletal Complications;   Pain;   Prostate Cancer;   Urinary Complications
    Intervention:   Drug: zoledronic acid
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Evaluation of RLY5016 in Heart Failure Patients

    Conditions:   Hyperkalemia;   Heart Failure
    Interventions:   Drug: Spironolactone + RLY5016;   Drug: Spironolactone + Placebo
    Sponsors:   Relypsa, Inc.;   Medpace, Inc.
    Recruiting - verified October 2009

  • Ixabepilone and Cyclophophamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Drug: Ixabepilone;   Drug: Cyclophosphamide
    Sponsors:   Sarah Cannon Research Institute;   SCRI Oncology Research Consortium;   Bristol-Myers Squibb
    Recruiting - verified November 2009

  • A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment

    Conditions:   Kidney Diseases;   Coronary Artery Disease
    Interventions:   Drug: regadenoson;   Drug: Placebo
    Sponsor:   Astellas Pharma Inc
    Recruiting - verified October 2009

  • Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed By Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

    Condition:   Breast Cancer
    Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Efficacy and Safety of TAK-491CLD in Subjects With Moderate to Severe Hypertension

    Condition:   Essential Hypertension
    Interventions:   Drug: TAK-491 and chlorthalidone;   Drug: TAK-491 and chlorthalidone;   Drug: Olmesartan medoxomil-hydrochlorothiazide
    Sponsor:   Takeda Global Research & Development Center, Inc.
    Recruiting - verified November 2009

  • Tanezumab In Osteoarthritis Of The Knee (2)

    Conditions:   Arthritis;   Osteoarthritis
    Interventions:   Biological: tanezumab 10 mg;   Biological: tanezumab 5 mg;   Drug: naproxen;   Other: placebo
    Sponsor:   Pfizer
    Recruiting - verified November 2009

  • An Open-Label Study of Trastuzumab-MCC-DM1 (T-DM1) vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer

    Condition:   Metastatic Breast Cancer
    Interventions:   Drug: capecitabine;   Drug: lapatinib;   Drug: trastuzumab-MCC-DM1
    Sponsors:   Genentech;   Roche Pharma AG
    Recruiting - verified October 2009

  • Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Drug: Ixabepilone;   Drug: Trastuzumab;   Drug: Carboplatin
    Sponsors:   Sarah Cannon Research Institute;   SCRI Oncology Research Consortium;   Bristol-Myers Squibb;   Genentech
    Recruiting - verified November 2009

  • Extension Study Of Tanezumab In Osteoarthritis

    Condition:   Osteoarthritis
    Interventions:   Biological: tanezumab;   Biological: tanezumab;   Biological: tanezumab
    Sponsor:   Pfizer
    Recruiting - verified November 2009

  • Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

    Conditions:   Menopause;   Osteoporosis
    Interventions:   Drug: bazedoxifene 20 mg/ conjugated estrogens 0.45 mg;   Drug: bazedoxifene 20 mg/ conjugated estrogens 0.625 mg;   Drug: bazedoxifene 20 mg;   Drug: conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg;   Drug: Placebo
    Sponsor:   Wyeth
    Recruiting - verified November 2009

  • Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

    Condition:   Cervical Cancer
    Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: paclitaxel;   Drug: topotecan hydrochloride
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

    Conditions:   Atherosclerosis;   Cardiovascular Disease;   Coronary Heart Disease;   CV Risk
    Interventions:   Drug: Darapladib;   Drug: Placebo
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxentan Efficacy and Safety Trial With a Randomized Prospective Assessment of Adding Sildenafil

    Conditions:   Pulmonary Arterial Hypertension;   Pulmonary Hypertension;   ETRA;   PAH
    Interventions:   Drug: Sitaxsentan;   Drug: Sitaxsentan and Sildenafil
    Sponsor:   Pfizer
    Recruiting - verified November 2009

    • Menu
    Find Paid Clinical Trials